SCM
LYEL icon

Sterling Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Sterling Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67K Buy
+190
New +$3.44K ﹤0.01% 2909
2025
Q2 		– Sell
-144
Closed -$1.55K – 3337
2025
Q1 		$1.55K Sell
144
-129
-47% -$1.58K ﹤0.01% 2675
2024
Q4 		$3.49K Buy
273
+247
+950% +$4.9K ﹤0.01% 2601
2024
Q3 		$704 Buy
+26
New +$764 ﹤0.01% 2712

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Sterling Capital Management's LYEL Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 190 shares worth $2.67K. The stake represents ﹤0.01% of the portfolio and ranks #2909 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in LYEL as recently as Q1 2025.

Sterling Capital Management first reported a position in LYEL in Q3 2024 and has held it in 4 quarters since. The position peaked at $3.49K in Q4 2024. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Sterling Capital Management held 190 shares of Lyell Immunopharma worth $2.67K as of Q2 2026.
  • Lyell Immunopharma was a new Sterling Capital Management position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2909 holding.
  • Sterling Capital Management first reported a position in Lyell Immunopharma in Q3 2024 and has held it in 4 quarters since.
  • Sterling Capital Management's Lyell Immunopharma position peaked at $3.49K in Q4 2024.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.